

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS



(Please scan this QR code to view the RHP)

This is an abridged prospectus containing salient features of the red herring prospectus of EMCURE PHARMACEUTICALS LIMITED (the "Company") dated [●] 2024 filed with the Registrar of Companies, Maharashtra at Pune. (the "RHP" or "Red Herring Prospectus"). You are encouraged to read greater details available in the RHP, which is available at <https://www.sebi.gov.in/sebiweb/home/HomeAction.do?doListing=yes&sid=3&ssid=15 &smid=11>. Unless otherwise specified all capitalised terms used herein and not specifically defined bear the same meaning as ascribed to them in the RHP. This abridged prospectus is not for distribution outside India.

THIS ABRIDGED PROSPECTUS CONSISTS OF FOUR PAGES OF BID CUM APPLICATION FORM ALONG WITH INSTRUCTIONS AND EIGHT PAGES OF ABRIDGED PROSPECTUS. PLEASE ENSURE THAT YOU HAVE RECEIVED ALL THE PAGES.

Please ensure that you have read the RHP, this abridged prospectus ("Abridged Prospectus") and the general information document for investing in public offers ("GID") undertaken through the Book Building Process before applying in the Offer (as defined below). The investors are advised to retain a copy of the RHP/Abridged Prospectus for their future reference. You may obtain a physical copy of the Bid cum Application Form and the RHP from the Stock Exchanges (defined below), Syndicate Member (defined below), Registrar to the Offer, Registrar and Share Transfer Agents ("RTAs"), Collecting Depository Participants ("CDPs"), Registered Brokers, Bankers to the Offer, Investors' Associations or Self-Certified Syndicate Banks ("SCSBs"). You may also download the RHP from the website of Securities and Exchange Board of India ("SEBI") at www.sebi.gov.in, at the websites of National Stock Exchange of India Limited ("NSE") and BSE Limited ("BSE", and together with NSE, the "Stock Exchanges") at www.nseindia.com and www.bseindia.com, respectively, and the websites of our Company at investors@emcure.com and at the website of the BRLMs at <https://investmentbank.kotak.com>; www.axiscapital.co.in; www.jefferies.com and www.jpmi.com

Emcure

EMCURE PHARMACEUTICALS LIMITED

Corporate Identity Number: U24231PN1981PLC024251; Date of Incorporation: April 16, 1981

REGISTERED AND CORPORATE OFFICE	CONTACT PERSON	E-MAIL AND TELEPHONE	WEBSITE
Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune 411 057, Maharashtra, India	Chetan Rajendra Sharma <i>Company Secretary and Compliance Officer</i>	E- mail: investors@emcure.com Tel: +91 20 3507 0033, +91 20 3507 0000	www.emcure.com

OUR PROMOTERS: SATISH RAMANLAL MEHTA, SUNIL RAJANIKANT MEHTA, NAMITA VIKAS THAPAR AND SAMIT SATISH MEHTA

DETAILS OF THE OFFER TO THE PUBLIC

Type Issue	Size of the Fresh Issue	Size of the Offer for Sale	Total Offer Size	Eligibility and Share Reservation	Equity Shares Reservation among QIBs, RIIs, NIIs and Employees			
					QIBs	NIBs	RIBs	Eligible
Fresh Issue and Offer for Sale	Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹8,000.00 million	Up to 11,428,839 Equity Shares of face value of ₹10 each aggregating up to ₹[●] million	Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹[●] million	The Offer is being made pursuant to Regulation 6(1) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements), 2018, as amended, ("SEBI ICDR Regulations"). For further details, see "Other Regulatory and Statutory Disclosures—Eligibility for the Offer" on page 466. For details in relation to share reservation among QIBs, NIBs, RIBs and Eligible Employees, see "Offer Structure" on page 489 of the RHP.	Not more than 50% of the Net Offer shall be available for allocation to QIBs. However, upto 5% of the Net QIB Portion shall be available for allocation proportionately to Mutual Funds only	Not less than 15% of the Net Offer or the Net Offer less allocation to QIBs and RIBs,	Not less than 35% of the Net Offer or Net Offer less allocation to QIBs and NIBs will be available for allocation.	Up to [●]% of the Offer size

These equity shares are proposed to be listed on the National Stock Exchange of India Limited ("NSE") and BSE Limited ("BSE" and together with NSE, the "Stock Exchanges"). For the purposes of the Offer, the Designated Stock Exchange shall be NSE. (the "Designated Stock Exchange").

DETAILS OF THE OFFER FOR SALE BY THE SELLING SHAREHOLDERS

NAME OF SELLING SHAREHOLDER#	TYPE	NUMBER OF EQUITY SHARES OFFERED	WEIGHTED AVERAGE COST OF ACQUISITION PER EQUITY SHARE (IN ₹)*
Satish Ramanlal Mehta	PSS	Up to 420,000 Equity Shares of face value of ₹10 each	19.37
Sunil Rajanikant Mehta***	PSS	Up to 40,000 Equity Shares of face value of ₹10 each	13.34
Namita Vikas Thapar	PSS	Up to 1,268,600 Equity Shares of face value of ₹10 each	3.44
Samit Satish Mehta	PSS	Up to 10,000 Equity Shares of face value of ₹10 each	5.43
Pushpa Rajnikant Mehta	PGSS	Up to 450,000 Equity Shares of face value of ₹10 each	0.04
Bhavana Satish Mehta**	PGSS	Up to 471,400 Equity Shares of face value of ₹10 each	4.30
Kamini Sunil Mehta	PGSS	Up to 125,000 Equity Shares of face value of ₹10 each	5.03
BC Investments IV Limited	ISS	Up to 7,234,085 Equity Shares of face value of ₹10 each	277.12
Arunkumar Purshotamlal Khanna	ID. SS	Up to 300,000 Equity Shares of face value of ₹10 each	2.41
Berjis Minoo Desai	OSS	Up to 144,642 Equity Shares of face value of ₹10 each	1.23
Sonali Sanjay Mehta	OSS	Up to 125,000 Equity Shares of face value of ₹10 each	7.96

*For a complete list of the PGSS and OSS, see "Annexure A" on page 541 of the RHP. ; *As certified by M/s R. B. Sharma and Co., Chartered Accountants, pursuant to their certificate dated [●], 2024. ; **Includes (i) 340,000 Equity Shares of face value of ₹10 each being offered by Bhavana Satish Mehta in her individual capacity; and (ii) 131,400 Equity Shares of face value of ₹10 each being offered by Bhavana Satish Mehta jointly with Satish Ramanlal Mehta, Bhavana Satish Mehta being the first holder. ; PSS: Promoter Selling Shareholder; ISS: Investor Selling Shareholder; PGSS: Promoter Group Selling Shareholder; OSS: Other Selling Shareholder; ID. SS: Individual Selling Shareholder; *** Equity Shares of face value of ₹10 each jointly held by Sunil Rajanikant Mehta with Kamini Sunil Mehta and Rutav Sunil Mehta, Sunil Rajanikant Mehta being the first holder.

PRICE BAND, MINIMUM BID LOT & INDICATIVE TIMELINES

Price Band#	₹ [●] to ₹ [●] per Equity Share of face value of ₹ 10/- each.
Minimum Bid Lot Size	[●] Equity Shares and in multiples of [●] Equity Shares thereafter
Bid/Offer Opens On ⁽¹⁾	[●] 2024
Bid/ Offer Closes On ^{(2),(3)}	[●] 2024
Bid/Offer Closing Date	[●] 2024
Finalisation of Basis of Allotment with the Designated Stock Exchange	On or about [●] 2024
Initiation of refunds (if any, for Anchor Investors)/unblocking of funds from ASBA Account*	On or about [●] 2024
Credit of Equity Shares of face value of ₹10 each to depository accounts	On or about [●] 2024
Commencement of trading of the Equity Shares of face value of ₹10 each on the Stock Exchanges	On or about [●] 2024

*For details of price band and basis of offer price, please refer to price band advertisement and page 164 of the RHP.

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

(1) Our Company, in consultation with the BRLMs, may consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bid/Offer Period will be one Working Day prior to the Bid/Offer Opening Date.
 (2) Our Company, in consultation with the BRLMs, may consider closing the Bid/Offer Period for QIBs one Working Day prior to the Bid/Offer Closing Date in accordance with the SEBI ICDR Regulations.
 (3) UPI mandate end time and date shall be at 5:00 pm on Bid/Offer Closing Date.

⁽ⁱ⁾ In case of (i) any delay in unblocking of amounts in the ASBA Accounts (including amounts blocked through the UPI Mechanism) exceeding two Working Days from the Bid/Offer Closing Date for cancelled / withdrawn / deleted ASBA Forms, the Bidder shall be compensated at a uniform rate of ₹100 per day or 15% per annum of the Bid Amount, whichever is higher from the date on which the request for cancellation/ withdrawal/ deletion is placed in the Stock Exchanges bidding platform until the date on which the amounts are unblocked; (ii) any blocking of multiple amounts for the same ASBA Form (for amounts blocked through the UPI Mechanism), the Bidder shall be compensated at a uniform rate of ₹100 per day or 15% per annum of the total cumulative blocked amount except the original application amount, whichever is higher from the date on which such multiple amounts were blocked till the date of actual unblock; (iii) any blocking of amounts more than the Bid Amount, the Bidder shall be compensated at a uniform rate of ₹100 per day or 15% per annum of the difference in amount, whichever is higher from the date on which such excess amounts were blocked till the date of actual unblock; (iv) any delay in unblocking of non-allotted/ partially allotted Bids, exceeding two Working Days from the Bid/Offer Closing Date, the Bidder shall be compensated at a uniform rate of ₹ 100 per day or 15% per annum of the Bid Amount, whichever is higher for the entire duration of delay exceeding two Working Days from the Bid/Offer Closing Date by the intermediary responsible for causing such delay in unblocking. The BRLMs shall, in their sole discretion, identify and fix the liability on such intermediary or entity responsible for such delay in unblocking. Further, the Bidder shall be compensated in the manner specified in the SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1M dated March 16, 2021, as amended pursuant to SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021 and SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/51 dated April 20, 2022, SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/2022/75 dated May 30, 2022, SEBI ICDR Master Circular and SEBI circular no. SEBI/HO/CFD/TPD1/CIR/P/2023/140 dated August 9, 2023, which for the avoidance of doubt, shall be deemed to be incorporated in the deemed agreement of the Company with the SCsBs, to the extent applicable. The processing fees for applications made by UPI Bidders may be released to the remitter banks (SCsBs) only after such banks provide a written confirmation on compliance with SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021 read with SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1M dated March 16, 2021, SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/51 dated April 20, 2022 and SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/2022/75 dated May 30, 2022. For more details in relation to the Bid/Offer Programme, please see page 485 of the RHP.

DETAILS OF WEIGHTED AVERAGE COST OF ACQUISITION OF ALL SHARES TRANSACTED IN THE LAST ONE YEAR, 18 MONTHS AND THREE YEARS PRECEDING THE DATE OF THE RED HERRING PROSPECTUS:

Period	Weighted average cost of acquisition (in ₹) **	Cap Price is 'X' times the weighted average cost of acquisition	Range of acquisition price: lowest price – highest price (in ₹) **
Last one year	1.75	1.0	165.07 – 465.82
Last 18 months	1.75	1.0	165.07 – 465.82
Last three years	2.51	1.0	165.07 – 862.09

*As certified by M/s R. B. Sharma and Co., Chartered Accountants, by way of their certificate dated [●], 2024. **Computed based on the Equity Shares of face value of ₹10 each acquired/allotted/purchased (including acquisition pursuant to transfer). However, the Equity Shares of face value of ₹10 each disposed off have not been considered while computing number of Equity Shares of face value of ₹10 each acquired. † The equity shares acquired by way of gift have not been considered for computing the range of acquisition price.

RISK IN RELATION TO THE FIRST OFFER

This being the first public issue of Equity Shares of our Company, there has been no formal market for the Equity Shares. The face value of the Equity Shares is ₹10. The Floor Price, Cap Price and Offer Price determined by our Company in consultation with the Book Running Lead Managers, on the basis of the assessment of market demand for the Equity Shares of face value of ₹10 each by way of the Book Building Process, as stated under “Basis for Offer Price” on page 163 of the RHP should not be considered to be indicative of the market price of the Equity Shares of face value of ₹10 each after the Equity Shares of face value of ₹10 each are listed. No assurance can be given regarding an active or sustained trading in the Equity Shares nor regarding the price at which the Equity Shares will be traded after listing.

GENERAL RISK

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares have not been recommended or approved by the Securities and Exchange Board of India (“SEBI”), nor does SEBI guarantee the accuracy or adequacy of the contents of the Red Herring Prospectus. Specific attention of the investors is invited to the section titled “Risk Factors” on page 42 of the RHP and on page [x] of this Abridged Prospectus.

PROCEDURE

You may obtain a physical copy of the Bid-cum-Application Form and the RHP from the Stock Exchanges, Syndicate Members, Registrar to the Offer, Registrar and Share Transfer Agents (“RTAs”), Collecting Depository Participants (“CDPs”), Registered Brokers, Bankers to the Offer, Investors’ Associations or Self Certified Syndicate Banks (“SCsBs”).

If you wish to know about processes and procedures applicable to the Offer, you may request for a copy of the RHP and/or the GID from the Book Running Lead Managers or download it from the website of SEBI at www.sebi.gov.in, the websites of NSE and BSE at www.nseindia.com and www.bseindia.com respectively and the website of Book Running Lead Managers at i.e., Kotak Mahindra Capital Company Limited at <https://investmentbank.kotak.com>, Axis Capital Limited at www.axiscapital.co.in, Jefferies India Private Limited at www.jefferies.com and J.P. Morgan India Private Limited at www.jpmi.com

PRICE INFORMATION OF BRLMs

S. No.	Issue name	Name of the merchant banker	+/- % change in closing price, +/- % change in closing benchmark		
			30 th calendar days from listing	90 th calendar days from listing	180 th calendar days from listing
1	Aadhar Housing Finance Limited	Kotak	+25.56%, [+5.40%]	Not applicable	Not applicable
2	Indegene Limited	Kotak, JPM	+24.28%, [+5.25%]	Not applicable	Not applicable
3	India Shelter Finance Corporation Limited	Kotak	+17.64%, [+1.48%]	+10.50%, [+4.28%]	+41.91%, [+10.95%]
4	Honasa Consumer Limited	Kotak, JPM	+17.58%, [+7.89%]	+34.77%, [+12.61%]	+29.68%, [+15.81%]
5	Cello World Limited	Kotak	+21.92%, [+7.44%]	+32.99%, [+12.58%]	+40.57%, [+15.78%]
6	Blue Jet Healthcare Limited	Kotak, JPM	+4.08%, [+6.02%]	+10.10%, [+14.47%]	+11.16%, [+18.07%]
7	JSW Infrastructure Limited	Kotak, Axis	+41.34%, [-2.93%]	+75.04%, [+10.27%]	+106.30%, [+12.42%]
8	Le Travenues Technology Limited	Axis	Not applicable	Not applicable	Not applicable
9	Awfis Space Solutions Limited	Axis	Not applicable	Not applicable	Not applicable
10	Go Digit General Insurance Limited	Axis	Not applicable	Not applicable	Not applicable
11	TBO Tek Limited	Axis, Jefferies	+69.94%, [+5.40%]	Not applicable	Not applicable
12	Bharti Hexacom Limited	Axis	+58.25%, [-2.13%]	Not applicable	Not applicable
13	Gopal Snacks Limited	Axis	-18.13%, [+1.57%]	-19.35%, [+4.60%]	Not applicable
14	Jana Small Finance Bank Limited	Axis	-5.23%, [+1.77%]	+50.70%, [+1.33%]	Not applicable
15	Entero Healthcare Limited	Jefferies	-19.65%, [-0.08%]	-18.73%, [+1.65%]	Not applicable
16	Concord Biotech Limited	Jefferies, Kotak	+36.82%, [+4.57%]	+ 83.91%, [+ 1.89%]	+88.78%, [+12.60%]
17	Mankind Pharma Limited	Jefferies, Kotak, JPM, Axis	+37.61%, [+2.52%]	+74.13%, [+6.85%]	+64.36%, [+5.28%]
18	KFin Technologies	Jefferies, Kotak, JPM	-13.55%, [-3.22%]	-24.56%, [-6.81%]	-4.48%, [+2.75%]
19	Global Health Limited	Jefferies, Kotak	+33.23%, [-0.03%]	+35.94%, [-3.47%]	+61.67%, [-0.52%]
20	TVS Supply Chain Solutions Limited	JPM, Axis	+8.7%, [+1.5%]	+6.6%, [+1.3%]	(7.5%), [+13.4%]
21	Life Insurance Corporation of India	JPM, Kotak, Axis	-27.2%, [-3.3%]	-28.1%, [+9.5%]	-33.8%, [+13.8%]

Source: www.nseindia.com and www.bseindia.com

Notes: 1. Disclosures subject to recent 7 issues (initial public offerings) in current financial year and two preceding financial years managed by each BRLMs with common issues disclosed once.; 2. Benchmark Index taken as NIFTY 50 or S&P BSE SENSEX, as applicable.; 3. Price on NSE or BSE is considered for all of the above calculations as per the Designated Stock Exchange disclosed by the respective issuer at the time of the issue, as applicable.; 4. In case 30th/90th/180th day is not a trading day, closing price of the previous trading

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

day has been considered.; 5. Since 30 calendar days, 90 calendar days and 180 calendar days, as applicable, from listing date has not elapsed for few of the above issues, data for same is not available.; 6. NA means Not Applicable - period not completed. For further details, please refer to "Other Regulatory and Statutory Disclosures - Price information of past issues handled by the Book Running Lead Managers (during current Financial Year and two Financial Years preceding the current Financial Year)" on page 473 of the RHP.

BOOK RUNNING LEAD MANAGERS

Kotak Mahindra Capital Company Limited Tel: +91 22 4336 0000 E-mail: emcure ipo@kotak.com Investor grievance e-mail: kmccredressal@kotak.com	Axis Capital Limited Tel: +91 22 4325 2183 E-mail: emcure ipo@axiscap.in Investor grievance e-mail: complaints@axiscap.in	Jefferies India Private Limited Tel: +91 22 4356 6000 E-mail: Emcure.IPO@jefferies.com Investor grievance e-mail: jipl.grievance@jefferies.com	J.P. Morgan India Private Limited Tel: +91 22 6157 3000 E-mail: EMCURE_IPO@jpmorgan.com Investor grievance e-mail: investorsmb.jpiml@jpmorgan.com
--	---	--	---

Name of Syndicate Member	Kotak Securities Limited
Name of Registrar to the Offer	Link Intime India Private Limited Tel: +91 810811 4949; E-mail: emcure ipo@linkintime.co.in; Investor Grievance E-mail: emcure ipo@linkintime.co.in
Name of Statutory Auditor	B S R & Co. LLP, Chartered Accountants
Name of Credit Rating Agency and the rating or grading obtained, if any	Not Applicable
Name of Debenture Trustee	As the Offer is of Equity Shares, no debenture trustee has been appointed for the Offer.
Self Certified Syndicate Banks or SCSB(s)	The list of SCSBs notified by SEBI for the ASBA process is available at http://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes , or at such other website as may be prescribed by SEBI from time to time. A list of the Designated SCSB Branches with which an ASBA Bidder (other than UPI Bidders), not Bidding through Syndicate/Sub Syndicate or through a Registered Broker, RTA or CDP may submit the Bid cum Application Forms, is available at https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=34 , or at such other websites as may be prescribed by SEBI from time to time.
Non-Syndicate Registered Brokers	Bidders can submit ASBA Forms in the Offer using the stockbroker network of the stock exchange, i.e., through the Registered Brokers at the Broker Centres. The list of the Registered Brokers eligible to accept ASBA Forms from Bidders (other than UPI Bidders), including details such as postal address, telephone number and e-mail address, is provided on the websites of the BSE and the NSE on the respective websites of the Stock Exchanges (www.bseindia.com and www.nseindia.com) For further details, see section titled "Offer Procedure" beginning at page 494 of the RHP.
Self-Certified Syndicate Banks and mobile applications enabled for UPI Mechanism	In accordance with SEBI circular No. SEBI/HO/CFD/DIL2/CIR/P/2019/76 dated June 28, 2019, SEBI circular No. SEBI/HO/CFD/DIL2/CIR/P/2019/85 dated July 26, 2019, and SEBI circular No. SEBI/HO/CFD/DIL2/CIR/P/2022/45 dated April 5, 2022, UPI Bidders may only apply through the SCSBs and mobile applications whose names appear on the website of the SEBI which may be updated from time to time. A list of SCSBs and mobile applications, using the UPI handles and which are live for applying in public issues using UPI mechanism is available on the website of SEBI at https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=40 and https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=43 , respectively, as updated from time to time and at such other websites as may be prescribed by SEBI from time to time.
Syndicate SCSB Branches	In relation to Bids (other than Bids by Anchor Investors and RIBs) submitted under the ASBA process to a member of the Syndicate, the list of branches of the SCSBs at the Specified Locations named by the respective SCSBs to receive deposits of Bid cum Application Forms from the members of the Syndicate is available on the website of the SEBI (https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=35) and updated from time to time or any other website as may be prescribed by SEBI from time to time or such other website as may be prescribed by SEBI from time to time.
Registered Brokers	Bidders can submit ASBA Forms in the Offer using the stock broker network of the Stock Exchange, i.e., through the Registered Brokers at the Broker Centres. The list of the Registered Brokers eligible to accept ASBA Forms, including details such as postal address, telephone number and e-mail address, is provided on the websites of the respective Stock Exchanges at www.bseindia.com and www.nseindia.com , as updated from time to time.
Details regarding website address(es)/ link(s) from which the investor can obtain a list of RTAs, CDPs and stock brokers who can accept applications from investors, as applicable:	The list of the RTAs eligible to accept ASBA Forms from Bidders (other than RIBs) at the Designated RTA Locations, including details such as address, telephone number and e-mail address, is provided on the websites of Stock Exchanges at http://www.bseindia.com/Static/Markets/PublicIssues/Rtadp.aspx ? and http://www.nseindia.com/products/content/equities/ijos/asba_procedures.htm , respectively, as updated from time to time. The list of the CDPs eligible to accept ASBA Forms from Bidders (other than RIBs) at the Designated CDP Locations, including details such as name and contact details, is provided on the websites of BSE at http://www.bseindia.com/Static/Markets/PublicIssues/Rtadp.aspx? and on the website of NSE at http://www.nseindia.com/products/content/equities/ijos/asba_procedures.htm , as updated from time to time. For further details, see "Offer Procedure" beginning on page 494 of the RHP.

PROMOTERS OF OUR COMPANY

Sr.	Name	Individual/Corporate	Experience & Educational Qualification
1.	Satish Ramanlal Mehta	Individual Promoter	He has been associated with our Company since its incorporation on April 16, 1981, as one of the first directors of our Company. He holds a master's degree in science (chemistry) from the University of Pune, Pune. He has also obtained a post graduate diploma in business administration from the Indian Institute of Management, Ahmedabad. He has significant experience in the pharmaceutical industry.
2.	Sunil Rajanikant Mehta	Individual Promoter	He has been associated with our Company since February 1, 1985, in the position as a manager of our Company. He holds a bachelor's degree in commerce from B.M. College of Commerce (University of Pune, Pune) and holds a master's diploma in business administration from the Institute of Management Development and Research, Pune.
3.	Namita Vikas Thapar	Individual Promoter	She has been associated with our Company since August 1, 2006, and was previously the chief financial officer of our Company. She is a qualified chartered accountant having passed the final examination held by ICAI in 1998. She holds a bachelor's degree in commerce from the University of Pune, Pune. She holds a master's degree in business administration from the Fuqua School of Business, Duke University, USA.
4.	Samit Satish Mehta	Individual Promoter	He has been associated with us since April 1, 2003, in various capacities such as the manager - business development and president - operations of our Company and has been our Whole-time Director since July 28, 2022. He holds a bachelor's degree in commerce from B. M. College of Commerce (University of Pune, Pune) and a master's degree in business administration from the Wharton School, University of Pennsylvania, Philadelphia.

For details in respect of the Promoters, please see the section entitled titled "Our Promoters and Promoter Group" beginning on page 306 of the RHP.

BUSINESS OVERVIEW AND STRATEGY

Company Overview: We are an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. We are a research and development ("R&D") driven company with a differentiated product portfolio that includes orals, injectables and biotherapeutics, which has enabled us to reach a range of target markets across over 70 countries, with a strong presence in India, Europe and Canada. In India, we are present across acute and chronic therapeutic areas, and our key therapeutic areas include gynecology, cardiovascular, vitamins, minerals and nutrients, human immunodeficiency virus antivirals, blood-related and oncology/anti-neoplastics.

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

Product Offering: We offer two types of products, namely formulations and active pharmaceutical ingredients (“APIs”). For further information, see “*Our Business – Our Product Offering*” on page 235 of the RHP. The following tables set forth a break-down of our revenue from the sale of our formulations and API products, in absolute terms and as a percentage of total revenue from sale of products, for the years indicated: (₹ in millions, except percentages)

	For the Financial Year ended March 31,					
	2024		2023		2022	
Formulations:						
Generic products	26,228.11	40.13%	20,114.16	34.24%	17,652.41	31.20%
Branded generics	34,541.93	52.84%	33,217.63	56.54%	34,015.82	60.11%
Branded patented products	1,802.45	2.76%	2,265.06	3.86%	2,586.23	4.57%
APIs	2,790.37	4.27%	3,146.41	5.36%	2,331.98	4.12%
Revenue from sale of products	65,362.86	100.00%	58,743.26	100.00%	56,586.44	100.00%

Key Performance Indicators (“KPI”): A list of our KPIs as of and for the Financial Years ended March 31, 2024, March 31, 2023, and March 31, 2022 is set out below:

(in ₹ million, unless otherwise indicated)

Particulars	For the Financial Year ended March 31,		
	2024	2023	2022
Percentage of revenue from operations attributable to sales in India (in %)	48.28	53.16	54.73
Percentage of revenue from operations attributable to sales outside India (in %)	51.72	46.84	45.27
EBITDA ⁽¹⁾	12,767.82	12,209.41	13,933.81
EBITDA Margin (in %) ⁽²⁾	19.01	20.24	23.54
PAT ⁽³⁾	5,275.75	5,618.45	7,025.56
PAT Margin ⁽⁴⁾	7.86	9.31	11.81
RoCE (in %) ⁽⁵⁾	19.37	22.01	29.69

Notes: 1. “EBITDA” is defined as earnings before interest, taxes, depreciation, and amortization; 2. “EBITDA Margin” is defined as our EBITDA during a given period as a percentage of total income during that period; 3. “PAT” is defined as profit for the year; 4. “PAT Margin” refers to profit after tax margin, is calculated by dividing our profit for a given year by total income for that year and is expressed as a percentage; 5. “RoCE” is calculated by dividing our EBIT for a given period by Capital Employed (i.e., total equity plus net debt) as of the end of that period and 6. EBITDA, EBITDA Margin, PAT Margin and RoCE are also Non-GAAP measures. For reconciliation of these numbers, see “Other Financial Information - Non-GAAP Measures” on page 409 of the RHP.

Geography Served: In addition to India, we also sell our products internationally in over 70 countries as of March 31, 2024, with Europe and Canada as our primary international markets. No single geography outside of India, Europe and Canada accounted for more than 5.00% of our revenue from operations for each of the Financial Years 2024, 2023 and 2022. The following tables set forth a break-down of our revenue from sales in India and sales outside India, in absolute terms and as a percentage of revenue from operations, for the years indicated: (₹ in millions, except percentages)

	For the Financial Year ended March 31,					
	2024		2023		2022	
Sales in India	32,148.98	48.28%	31,818.18	53.16%	32,046.66	54.73%
Sales outside India	34,433.53	51.72%	28,039.93	46.84%	26,507.21	45.27%
Revenue from operations	66,582.51	100.00%	59,858.11	100.00%	58,553.87	100.00%

Client profile or Industries served: Pharmaceutical. For further details, see “*Industry Overview*” beginning on page 181 of the RHP.

Intellectual Property: As of March 31, 2024, we had been granted 220 patents and had 30 pending patent applications in several countries, and had submitted 102 DMFs for APIs with the USFDA. In addition, we have obtained registration for or have applied for registration under the Trademarks Act in respect of our top brands under various classes. As of March 31, 2024, we held 2,402 registered trademarks including for our OROFER, METPURE, LOMOH, SPEGRA, ENCICARB, TEMSAN and EXAFIB brands, and had 508 pending trademark applications. As of March 31, 2024, we held 56 copyrights and one pending copyright application.

Market Share: We were ranked as (i) the 13th largest pharmaceutical company in India in terms of Domestic Sales for MAT Financial Year 2024, (ii) the 4th largest pharmaceutical company by market share in our Covered Markets in terms of Domestic Sales for MAT Financial Year 2024, and (iii) the largest pharmaceutical company in the gynecology and HIV antivirals therapeutic areas in India in terms of Domestic Sales for MAT Financial Year 2024 (Source: CRISIL Report)

Manufacturing Plant: We have 13 manufacturing facilities across the states of Maharashtra, Gujarat, Sikkim and Karnataka and the union territory of Jammu and Kashmir, in India, 11 of which are situated on leasehold land. For further details, please see “*Our Business – Manufacturing Facilities*” on page 236 of the RHP.

Employee Strength: As of March 31, 2024, we had 11,146 permanent employees. For further details, please see “*Our Business - Employees*” on page 247 of the RHP.

OUR MANAGEMENT

Name	Designation	Experience and Educational Qualification	Other directorship
Berjis Minoos Desai	Chairman and Non-Executive Director	He has been on the Board of our Company since April 3, 1997. He holds a bachelor's degree in law from Government Law College (University of Bombay, Mumbai) and a master's degree in law from the University of Cambridge, United Kingdom. He has experience in private client practice, business laws, transactional and dispute resolution. He was previously associated as a managing partner with J. Sagar Associates, Advocates & Solicitors.	Indian Companies: • Jubilant FoodWorks Limited; • The Great Eastern Shipping Company Limited; • Man Infraconstruction Limited; • Inventurus Knowledge Solutions Limited; • Vista Intelligence Private Limited; • Ambit Private Limited; • Chambal Fertilisers and Chemicals Limited; and • Hikal Limited Foreign Companies: Nil
Satish Ramanlal Mehta	Managing Director and Chief Executive Officer	He has been associated with our Company since its incorporation on April 16, 1981, as one of the first directors of our Company. He holds a master's degree in science (chemistry) from the University of Pune, Pune. He has also obtained a post graduate diploma in business administration from the Indian Institute of Management, Ahmedabad. He has significant experience in the pharmaceutical industry.	Indian Companies: • Gennova Biopharmaceuticals Limited; and • Zuventus Healthcare Limited Foreign Companies: Nil
Sunil Rajanikant Mehta	Whole-time Director	He has been associated with our Company since February 1, 1985, in the position as a manager of our Company. He holds a bachelor's degree in commerce from B.M. College of Commerce (University of Pune, Pune) and holds a master's diploma in business administration from the Institute of Management Development and Research, Pune.	Indian Companies: • Gennova Biopharmaceuticals Limited Foreign Companies: Nil

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

Name	Designation	Experience and Educational Qualification	Other directorship
Namita Vikas Thapar	Whole-time Director	She has been associated with our Company since August 1, 2006, and was previously the chief financial officer of our Company. She is a qualified chartered accountant having passed the final examination held by ICAI in 1998. She holds a bachelor's degree in commerce from the University of Pune, Pune. She holds a master's degree in business administration from the Fuqua School of Business, Duke University, USA.	Indian Companies: • Zuventus Healthcare Limited; • Thapar Ventures Private Limited; • Incredible Ideas Private Limited; and • Incredible Ventures Private Limited. Foreign Companies: Nil
Samit Satish Mehta	Whole-time Director	He has been associated with us since April 1, 2003, in various capacities such as the manager – business development and president - operations of our Company and has been our Whole-time Director since July 28, 2022. He holds a bachelor's degree in commerce from B. M. College of Commerce (University of Pune, Pune) and a master's degree in business administration from the Wharton School, University of Pennsylvania, Philadelphia.	Indian Companies: • Uth Beverage Factory Private Limited; and • Gennova Biopharmaceuticals Limited Foreign Companies: • Emcure Pharma UK Limited; and • Tillomed Laboratories Limited
Mukund Keshao Gurjar	Whole-time Director	He has been associated with our Company since July 23, 2001, as a Director of our Company. He holds a bachelor's degree in science, a master's degree in science and qualified as a doctor of philosophy in the faculty of science from the Nagpur University. He also holds a degree of doctor of philosophy from the Queen Elizabeth College, University of London. Prior to joining our Company, he was working with the National Chemical Laboratory, Pune for 24 years. He has received a certificate of appreciation in recognition of 17 years of his valued services as an editorial advisory board member for Organic Process Research & Development, American Chemical Society. For his contributions to synthetic organic chemistry involving both basic and applied research, he has been felicitated with various awards.	Indian Companies: Nil Foreign Companies: Nil
Samonoi Banerjee⁽¹⁾	Non-Executive Director	He holds a bachelor's degree in engineering and a master's degree in science from the Birla Institute of Technology and Science, Pilani. He holds a master's degree in business administration from the Wharton School of the University of Pennsylvania, Philadelphia. He has previously worked with McKinsey & Company, Inc. as engagement manager (management consultant) and Accenture India Private Limited as a consultant.	Indian Companies: Nil Foreign Companies: Nil
Palamadai Sundararajan Jayakumar	Independent Director	He holds a master's degree in commerce from the University of Chennai. He is a qualified chartered accountant with the ICAI. He holds a post graduate diploma in business management from Xavier Labour Related Institute, Jamshedpur. He has previously worked with Citibank N.A and was also the managing director and chief executive officer of VBHC Value Homes Private Limited. Further, he was the managing director and chief executive officer of Bank of Baroda for a period of three years until October 2018 which was further extended for a period of one year till October 2019.	Indian Companies: • Tata Motors Finance Limited; • Adani Ports and Special Economic Zone Limited; • JM Financial Limited; • CG Power and Industrial Solutions Limited; • VBHC Value Homes Private Limited; • TVS Industrial and Logistics Parks Private Limited; • TVS Infrastructure Investment Manager Private Limited; • Adani Logistics Limited; • Northern ARC Capital Limited; • HT Media Limited; • Progrow Farm and Rural Mission Private Limited; • Zuventus Healthcare Limited; and • Future Generali India Life Insurance Company Limited Foreign Companies: Nil
Vijay Keshav Gokhale	Independent Director	He holds a bachelor's and a master's degree in arts from the University of Delhi, New Delhi. He joined the Indian foreign services in 1981 and retired as foreign secretary in 2020. In the past, he has been appointed as a High Commissioner of India to Malaysia as well as an Ambassador of India to the Federal Republic of Germany and the People's Republic of China.	Indian Companies: • Zuventus Healthcare Limited Foreign Companies: Nil
Vidya Rajiv Yeravdekar	Independent Director	She holds a degree in doctor of medicine and bachelor's degree in law from the University of Pune, Pune. She also holds a degree in doctor of philosophy from Symbiosis International University, Pune. She is a principal director of Symbiosis Society, and the pro Chancellor of Symbiosis International University. She has previously served as the joint director of Symbiosis Society and director of Symbiosis Centre of Health Care.	Indian Companies: • Apical Hospitality Services Private Limited; • Maharashtra Chamber of Commerce Industries and Agriculture; • Apical Academic Infrastructure and Communication Private Limited; • Symbiosis Centre for Entrepreneurship and Innovation; • Bajaj Holdings & Investment Limited Foreign Companies: Nil
Shailesh Kripalu Ayyangar	Independent Director	He holds a bachelor's degree in veterinary science and animal husbandry from the Faculty of Veterinary Science and Animal Husbandry (Gujarat Agricultural University) and a post graduate diploma in management from the Indian Institute of Management, Ahmedabad. He was previously associated with Sanofi India Limited as its managing director and later as its non-executive director and with Sanofi Synthelabo (India) Private Limited as its managing director and head of strategic projects.	Indian Companies: • Shaily Engineering Plastics Limited; • Noveltech Feeds Private Limited; • Zuventus Healthcare Limited; • Gennova Biopharmaceuticals Limited; and • Universal Nutriscience Private Limited Foreign Companies: Nil

(1) Nominated by BC Investments IV Limited

For further details in relation to our Board of Directors, see **"Our Management"** beginning on page 284 of the RHP.

OBJECTS OF THE OFFER

The Offer comprises the Fresh Issue of up to [●] Equity Shares of face value of ₹10 each, aggregating up to ₹8,000.00 million by our Company and an Offer for Sale of up to 11,428,839 Equity Shares of face value of ₹10 each aggregating up to ₹[●] million by the Selling Shareholders. For further details of the Offer for Sale, see **"The Offer"** on page 97 of the RHP.

Offer for Sale: The Selling Shareholders will be entitled to the proceeds from the sale of their respective portion of the Offered Shares in the Offer for Sale, net of their respective share of the Offer related expenses and relevant taxes thereon. Our Company will not receive any proceeds from the Offer for Sale and the proceeds received from the Offer for Sale will not form a part of the Net Proceeds. For further details, see **"– Offer Expenses"** on page 159 of the RHP.

Net Proceeds: Our Company proposes to utilise the Net Proceeds towards funding of the following objects:

1. Repayment and/ or prepayment of all or a portion of certain outstanding borrowings availed by our Company; and
2. General corporate purposes.

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

Fresh Issue : The details of the proceeds from the Fresh Issue are set forth in the table below:

(in ₹ million)

Particulars	Estimated amount
Gross Proceeds	8,000.00
(Less) estimated expenses in relation to Fresh Issue ⁽¹⁾⁽²⁾	[-]
Net Proceeds⁽¹⁾	[-]

(1) To be finalised upon determination of the Offer Price and updated in the Prospectus prior to filing with RoC.; (2) For details of the expenses related to the Offer, see “ – Offer Expenses” on page 159 of the RHP.

Proposed schedule of implementation and deployment of Net Proceeds : The following table sets forth the details of the schedule of the expected deployment of the Net Proceeds: (in ₹ million)

Particulars	Amount to be funded from the Net Proceeds	Estimated deployment	
		Fiscal 2025	Fiscal 2026
Repayment and/ or prepayment of all or a portion of certain outstanding borrowings availed by our Company	6,000.00	6,000.00	-
General corporate purposes [†]	[-]	[-]	[-]
Total	[-]	[-]	[-]

[†] To be finalised upon determination of the Offer Price and updated in the Prospectus prior to filing with RoC. The amount utilised for general corporate purposes shall not exceed 25% of the Gross Proceeds.

Means of finance: The fund requirements set out above are proposed to be funded from the Net Proceeds. Accordingly, we confirm that there are no requirements to make firm arrangements of finance under Regulation 7(1)(e) of the SEBI ICDR Regulations through verifiable means towards at least 75% of the stated means of finance, excluding the amount to be raised from the Fresh Issue and existing identifiable accruals, as prescribed under the SEBI ICDR Regulations.

Details and reasons for non-deployment or delay in deployment of proceeds or changes in utilisation of issue proceeds of past public offers / rights issues, if any, of the Company in the preceding 10 years: Not Applicable

Terms of Issuance of Convertible Security, if any: Not Applicable

Name of Monitoring Agency: CARE Ratings Limited

Shareholding Pattern as on the date of the RHP:

Category of shareholder	Pre-Offer Number of Fully Paid-up Equity Shares of face value ₹10	% holding of Pre-Offer Equity Share capital
Promoters and Promoter Group	150,730,468	83.21
Public	30,421,648	16.79
Total	181,152,116	100.00

Number of Equity Shares proposed to be sold by Selling Shareholders:

Sr. No.	Name of the Selling Shareholder	Type	Maximum number of Offered Shares
1	Satish Ramanlal Mehta	PSS	420,000
2	Sunil Rajanikant Mehta**	PSS	40,000
3	Namita Vikas Thapar	PSS	1,268,600
4	Samit Satish Mehta	PSS	10,000
5	Pushpa Rajnikant Mehta	PGSS	450,000
6	Bhavana Satish Mehta*	PGSS	471,400
7	Kamini Sunil Mehta	PGSS	125,000
8	Rutav Sunil Mehta	PGSS	110,000
9	Swati Hetalkumar Shah (jointly with Hetal Rasiklal Shah)	PGSS	64,500
10	Shailesha Sharad Gujar	PGSS	51,686
11	Sanjay Rajanikant Mehta (jointly with Sonali Mehta and Manan Mehta)	PGSS	40,000
12	Vikas Madan Thapar	PGSS	30,000
13	BC Investments IV Limited	ISS	7,234,085
14	Arunkumar Purshotamlal Khanna	ID. SS	300,000
15	Berjis Minoo Desai	OSS	144,642
16	Sonali Sanjay Mehta	OSS	125,000
17	Manan Sanjay Mehta	OSS	110,000
18	Prakash Kumar Guha	OSS	100,000
19	Shreekant Krushnaji Bapat (jointly with Alaka Shreekant Bapat)	OSS	75,000
20	Smita Dilip Shah	OSS	66,000
21	Shriram Balasubramanian	OSS	25,000
22	Usha Jashvantlal Shah	OSS	25,000
23	Jashvantlal Chandulal Shah	OSS	20,000
24	Devalaji U (jointly with Himabindu D)	OSS	17,356
25	Hitesh Sohanlal Jain	OSS	13,000
26	Jini Dhanrajgir	OSS	92,570

*Includes (i) 340,000 Equity Shares of face value of ₹10 each being offered by Bhavana Satish Mehta in her individual capacity; and (ii) 131,400 Equity Shares of face value of ₹10 each being offered by Bhavana Satish Mehta jointly with Satish Ramanlal Mehta, Bhavana Satish Mehta being the first holder.

** Equity Shares of face value of ₹10 each jointly held by Sunil Rajanikant Mehta with Kamini Sunil Mehta and Rutav Sunil Mehta, Sunil Rajanikant Mehta being the first holder.

SUMMARY OF RESTATED CONSOLIDATED FINANCIAL INFORMATION

(₹ in million, unless otherwise specified)

Particulars	As at and for the financial year ended March 31, 2024 [†]	As at and for the financial year ended March 31, 2023	As at and for the financial year ended March 31, 2022
Revenue from operations	66,582.51	59,858.11	58,553.87
Profit before exceptional items and tax	7,371.59	7,533.61	9,725.48
Profit for the year	5,275.75	5,618.45	7,025.56

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

Particulars	As at and for the financial year ended March 31, 2024	As at and for the financial year ended March 31, 2023	As at and for the financial year ended March 31, 2022
Equity share capital	1,811.52	1,808.52	1,808.52
Other equity	27,711.31	23,202.74	18,066.96
Net worth ⁽¹⁾	29,522.83	25,011.26	19,875.48
Basic earnings per share ⁽²⁾ (₹)	27.54	29.42	36.62
Diluted earnings per share ⁽³⁾ (₹)	27.54	29.42	36.62
Return on Net Worth (%) ⁽⁴⁾	16.87	21.27	33.32
Net Asset Value per Equity Share ⁽⁵⁾ (₹)	163.22	138.30	109.90

Notes: (1) Net Worth means total equity attributable to the owners of the Company; (2) Basic earnings per share: Net Profit after tax attributable to equity Shareholders for the period by the weighted average number of equity shares outstanding during the reporting period; (3) Diluted earnings per share: Net Profit after tax attributable to equity Shareholders for the period by the weighted average number of equity shares and equivalent dilutive equity shares outstanding during the reporting period; (4) Return on Net Worth is the restated profit attributable to owners of the Company divided by the Total Equity attributable to owners of the Company at the end of year; (5) Net Asset Value per Equity Share is equal to net worth divided by weighted average number of Equity Shares of face value of ₹10 each outstanding during the year.

For further details, see "Financial Statements" on page 312 of the RHP.

INTERNAL RISK FACTORS

Below mentioned risks are the top 5 risk factors as per the RHP. For further details, see "Risk Factors" on page 42 of the RHP.

1. Any manufacturing or quality control problems may damage our reputation, subject us to regulatory action, and expose us to litigation or other liabilities, which could adversely affect our reputation, business, financial condition and results of operations.
2. Our failure to comply with applicable quality standards may result in product liability claims, which could adversely affect our business, financial condition, cash flows and results of operations.
3. Our manufacturing and research and development operations are subject to operational risks. Any slowdown or shutdown in our manufacturing or research and development operations could adversely affect our business, financial condition and results of operations.
4. We are subject to extensive government regulations in India and our international markets, and if we fail to obtain, maintain or renew our statutory and regulatory licenses, permits and approvals required to operate our business, our business, financial condition, results of operations and cash flows may be adversely affected.
5. Any disruptions to the supply, or increases in the pricing, of the raw materials and finished products that we outsource, may adversely affect the supply and pricing of our products and, in turn, adversely affect our business, cash flows, financial condition and results of operations.

For further details, see "Risk Factors" beginning on 42 of the RHP.

SUMMARY OF OUTSTANDING LITIGATIONS, CLAIMS AND REGULATORY ACTION

A. A summary of outstanding litigation proceedings involving our Company, our Directors, our Promoters and our Subsidiaries as on the date of the Red Herring Prospectus as disclosed in the section titled "Outstanding Litigation and Material Developments" on page 446 of the Red Herring Prospectus in terms of the SEBI ICDR Regulations is provided below.

Name of Entity	Criminal Proceedings	Tax Proceedings	Statutory or Regulatory Proceedings ⁽¹⁾	Disciplinary actions by the SEBI or Stock Exchanges against our Promoters in the last five financial years	Material civil litigation ^(**)	Total aggregate amount involved ^(*) (in ₹ million)
Company						
By our Company	22	Nil	Nil	N.A.	Nil	34.06
Against our Company	1	36	5	N.A.	1	2,146.87
Directors						
By our Directors	Nil	Nil	Nil	N.A.	Nil	Nil
Against our Directors	7	Nil	5 ³	N.A.	1	53.61
Promoters						
By the Promoters	Nil	Nil	Nil	Nil	Nil	Nil
Against our Promoters	3	Nil	5 ³	Nil	1	53.61
Subsidiaries						
By our Subsidiaries	23	Nil	Nil	N.A.	1	1,067.12
Against our Subsidiaries	2	42	1	N.A.	1	1,368.29

*Amount to the extent quantifiable; **In accordance with the Materiality Approach; ³It is clarified that these are the same matters that are outstanding against our Company and one of our Subsidiaries, to which certain of our Directors/ Promoters are also parties

⁽¹⁾ To the extent quantifiable, the monetary claims under the actions taken by statutory or regulatory authorities, in India and outside India, against our Company and its Subsidiaries is provided below:

S. No.	Particulars	Monetary impact (in ₹ million)
1	Actions taken by statutory or regulatory authorities outside India	Nil
2	Actions taken by statutory or regulatory authorities in India	53.61

For further details, see "Outstanding Litigation and Material Developments" on page 446 of the RHP.

B. Brief details of top 5 material outstanding litigations against the Company and amount involved

Sr. No.	Particulars	Litigation filed by	Current Status	Amount involved (in ₹ million)
1	Our Company, four of our Directors and certain other individuals were in receipt of nine show cause notices dated March 12, 2019 ("Noticees") issued by Registrar of Companies, Pune ("RoC") alleging violations under the Companies Act, 2013, post an inspection notice dated August 26, 2016 issued by Regional Director, Western Region, Ministry of Corporate Affairs ("Regional Director"). Thereafter, our Company filed nine compounding applications with the Regional Director. The Noticees requested the RoC to drop and annul the action under the respective show cause notices. Of the total nine compounding applications (of which four were withdrawn), the Regional Director had compounded the offences and imposed a monetary fee of a total amount of ₹1.70 million on the Noticees, which was paid by them in December 2019 and the resolution of the subject matter of the remaining four show case notices remains pending.	Regional Director, Western Region, Ministry of Corporate Affairs	Pending	Not quantifiable

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

2	Based on certain complaints received by the Competition Commission of India (“CCI”), the CCI <i>vide</i> its order dated July 5, 2017 (“CCI Order”) formed a <i>prima facie</i> opinion that there was price coordination amongst our Company and three other pharmaceutical companies (“Defendants”). The CCI directed the Director General to conduct further investigation into the matter of violation of the Competition Act, 2022. Our Company filed an application for review/ recall of the CCI Order (“Application”), however, it was disposed of by the CCI (“CCI Order II”). Thereafter, our Company filed a civil writ petition before the Delhi High Court for setting aside the CCI Order and CCI Order II and the Delhi High Court set aside CCI Order II and directed the CCI to pass a fresh order on the Application after providing our Company an opportunity of being heard. The CCI, pursuant to a hearing with our Company, rejected the Application. A special leave to appeal was filed by one of the Defendants, before the Supreme Court of India, pursuant to which the Supreme Court of India directed that a ‘ <i>status quo</i> ’ should be maintained by the parties in relation to the subject matter until further orders.	Competition Commission of India	Pending	Not quantifiable
3	A compliant dated July 12, 2004 was filed against our Company, its then chairman, our Managing Director and Chief Executive Officer and certain employees before the Chief Judicial Magistrate, Saharsa, Bihar (“CJM-S”) alleging manufacturing, distribution and sale of misbranded drugs and violation of provisions of the Drugs and Cosmetics Rules, 1945 and Drugs and Cosmetics Act, 1940. By an order dated July 12, 2004, summons were issued to our Company and other accused and the matter was transferred to the Judicial Magistrate, First Class, Saharsa, Bihar for trial and disposal. Subsequently, by an order of the CJM-S, the matter has been transferred to the Court of Chief Judicial Magistrate, Patna, Sadar. (“Saharsa Matter”)	State of Bihar (through the Inspector of Drugs)	Pending	Not quantifiable
4	Our Company, Heritage and our Managing Director and Chief Executive Officer, Satish Ramanlal Mehta, together with other generic pharmaceutical drug manufacturers, were named as defendants in civil proceedings in the United States, including class-action cases (the “Civil Cases”) and complaints filed by U.S. state attorneys-general (the “State AG Complaint”) alleging that the defendants entered into product-specific conspiracies to restrain trade in violation of federal and state antitrust laws and other state laws. Our Company, Heritage and Satish Ramanlal Mehta have entered into (i) settlement agreements dated October 31, 2023 and November 28, 2023 with certain plaintiffs in the Civil Cases, which are currently pending approval by the relevant U.S. court; and (ii) a settlement agreement with the plaintiff states in the State AG Complaint, which was approved and became final on June 12, 2024.	Civil Cases: Putative classes and individual opt-out plaintiffs State AG Complaint: Attorneys-general of 47 U.S. states and several U.S. territories	Civil Cases: Settlements with certain plaintiffs reached and pending court approval State AG Complaint: Settlement finalized	US\$30 million (approximately ₹2,501.10 million*) *Based on the exchange rate of US\$1 = ₹83.37, as of March 31, 2024.
5	Pursuant to the search and seizure operations conducted by the Income Tax Department in December 2020, our Company had received assessment orders and notices of demand under the Income Tax Act, 1961 for the assessment year 2016 to assessment year 2022 (“Demand Notices”) for an aggregate amount of ₹1,621.04 million payable on account of disallowance of certain expenses. Our Company has filed appeals each dated December 27, 2023 against such orders, before the Commissioner of Income Tax (Appeals).	Income Tax Department	Pending	₹1,621.04

C. **Regulatory Action, if any – disciplinary action taken by SEBI or Stock Exchanges against the Promoters in last 5 financial years including outstanding action, if any:** Nil

D. **Brief details of outstanding criminal proceedings against our Promoters**

Sr. No.	Particulars	Litigation filed by	Current Status	Amount involved (in ₹ million)
1	Our Promoter, Satish Ramanlal Mehta is party to the Sahara Matter wherein a compliant dated July 12, 2004 was filed against our Company, its then chairman, our Managing Director and Chief Executive Officer (Satish Ramanlal Mehta) and certain employees before the Chief Judicial Magistrate, Saharsa, Bihar (“CJM-S”) alleging manufacturing, distribution and sale of misbranded drugs and violation of provisions of the Drugs and Cosmetics Rules, 1945 and Drugs and Cosmetics Act, 1940. By an order dated July 12, 2004, summons were issued to our Company and other accused and the matter was transferred to the Judicial Magistrate, First Class, Saharsa, Bihar for trial and disposal. Subsequently, by an order of the CJM-S, the matter has been transferred to the Court of Chief Judicial Magistrate, Patna, Sadar.	State of Bihar (through the Inspector of Drugs)	Pending	Not quantifiable
2	The Drugs Control Officer, Sawai Madhopur (“Drugs Control Officer”) filed a criminal case before the Chief Judicial Magistrate, Sawai Madhopur (“CJM-S”) and before the Chief Judicial Magistrate, Baran (“CJM-B”) against Zuventus and its directors, including our Promoter, Satish Ramanlal Mehta, alleging violation of certain provisions of the D&C Act. Zuventus and its directors, including Satish Ramanlal Mehta, received summons from the CJM-S and CJM-B, requiring them to appear before respective courts. Subsequently, Zuventus and Satish Ramanlal Mehta filed four separate criminal miscellaneous petitions under Section 482 of CrPC before the High Court of Judicature for Rajasthan, Jaipur (“High Court”) praying for quashing of the summoning order and the entire proceedings before the CJM-S and CJM-B. The High Court <i>vide</i> order dated April 25, 2023 has put in abeyance the operation of arrest warrants issued in the CJM-B matter.	Drug Control Officer	Pending	Not quantifiable

For further details of the outstanding litigation matters, see “*Outstanding Litigation and Material Developments*” on page 446 of the RHP.

ANY OTHER IMPORTANT INFORMATION AS PER BRLMs/COMPANY - NIL

DECLARATION BY OUR COMPANY

We hereby certify and declare that all relevant provisions of the Companies Act and the rules, regulations and guidelines issued by the Government of India, or the rules, regulations or guidelines issued by the SEBI, established under Section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with, and no statement made in the Red Herring Prospectus is contrary to the provisions of the Companies Act, the Securities Contracts (Regulation) Act, 1956, the Securities Contract (Regulation) Rules, 1957 and the Securities and Exchange Board of India Act, 1992, each as amended, or the rules, regulations or guidelines issued thereunder, as the case may be. We further certify that all the statements and disclosures made in the Red Herring Prospectus are true and correct.

DECLARATION BY THE SELLING SHAREHOLDER

Each Selling Shareholder, severally and not jointly, accepts responsibility for only such statements specifically confirmed or made by such Selling Shareholder in the Red Herring Prospectus to the extent such statements pertain to such Selling Shareholder and/or its respective portion of the Offered Shares and confirms that such statements are true and correct in all material respects and are not misleading in any material respect. Each of the Selling Shareholders, severally and not jointly, assume no responsibility for any other statement in the Red Herring Prospectus, including, inter alia, any of the statements made by or relating to our Company, its business, any other Selling Shareholder or any other person(s)